An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Icrucumab (Primary) ; Ramucirumab (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 04 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 16 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
- 07 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.